SCIENTIA ADVISORS: NEWS
Release Date: 09/04/2007Scientia Advisors Management Consultant and Managing Partner, Harry Glorikian, will be a speaker at Mintz Levin, Boston MA - on "Capitalizing on Convergence" Challenges posed by combination medical products – September 19, 2007
The convergence of the biological revolution with medical devices holds the promise of a new stream of innovations. Many medical device companies are grappling with how to manage product innovation and development so as to take advantage of the biological revolution. The goal of this presentation is to explore the challenges and opportunities for device companies that this convergence presents.
The presentation will provide an overview of the scientific state of the art and the strategies being employed as the convergence of biologics and engineered technologies is unfolding. There will be an analysis of the economic opportunity that this convergence presents for the device industry and for regional and national economic development. The regulatory and reimbursement issues unique to these potential products will be discussed, and we will look at case studies of firms that have combination products currently on the market, exploring the variety of ways these firms have adapted to scientific, regulatory and market challenges. Finally, we will conclude with a discussion of the strategic challenges and business models that will need to emerge to successfully navigate in this exciting and innovative area.
Harry Glorikian’s experience allows him to cover a broad range of areas within life sciences. His direct experience in sales, marketing, business development, and intellectual property combined with his technical and market knowledge provides unique and insightful perspectives. Harry has 15 years of experience in the life sciences developing and executing key strategic acquisitions and licensing arrangements targeting revenue growth channels. Harry currently leads Scientia, including the management of consulting teams, new business development, and intellectual capital development. His client engagements have involved comprehensive go-to-market plans in the areas of diagnostics, genomic, proteomics, cell biology, cellular therapy and consumables & services groups. His clients include both emerging innovators and global market leaders.
Click here to download PDF versionThe presentation will provide an overview of the scientific state of the art and the strategies being employed as the convergence of biologics and engineered technologies is unfolding. There will be an analysis of the economic opportunity that this convergence presents for the device industry and for regional and national economic development. The regulatory and reimbursement issues unique to these potential products will be discussed, and we will look at case studies of firms that have combination products currently on the market, exploring the variety of ways these firms have adapted to scientific, regulatory and market challenges. Finally, we will conclude with a discussion of the strategic challenges and business models that will need to emerge to successfully navigate in this exciting and innovative area.
Harry Glorikian’s experience allows him to cover a broad range of areas within life sciences. His direct experience in sales, marketing, business development, and intellectual property combined with his technical and market knowledge provides unique and insightful perspectives. Harry has 15 years of experience in the life sciences developing and executing key strategic acquisitions and licensing arrangements targeting revenue growth channels. Harry currently leads Scientia, including the management of consulting teams, new business development, and intellectual capital development. His client engagements have involved comprehensive go-to-market plans in the areas of diagnostics, genomic, proteomics, cell biology, cellular therapy and consumables & services groups. His clients include both emerging innovators and global market leaders.
